Lymphokines, E.g., Interferons, Interlukins, Etc. Patents (Class 530/351)
-
Patent number: 8383774Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.Type: GrantFiled: July 10, 2008Date of Patent: February 26, 2013Assignee: Apogenix GmbHInventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
-
Publication number: 20130045480Abstract: The present invention provides dyes, reactive dyes and labeled reagents that may be used in the detection or quantification of desirable target molecules, such as proteins and nucleic acids. Dyes are provided that may be used free in solution where the binding of the dye to the target molecule provides signal generation. Dyes are also provided that comprise reactive groups that may be used to attach the dyes to probes that will bind to desirable target molecules. The novel dyes of the present invention have been modified by the addition of charged and polar groups to provide beneficial properties.Type: ApplicationFiled: June 17, 2009Publication date: February 21, 2013Applicant: ENZO LIFE SCIENCES, INC. C/O ENZO BIOCHEM, INC.Inventors: Yuejun Xiang, Praveen Pande, Rajesh Khazanchi, Elazar Rabbani, Dakai Liu, Wei Cheng
-
Patent number: 8377438Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.Type: GrantFiled: December 20, 2011Date of Patent: February 19, 2013Assignee: ZymoGenetics, Inc.Inventors: Yue Yao, Janine Bilsborough
-
Patent number: 8377882Abstract: Disclosed is a composition including IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum. Also disclosed is a kit including a composition or a lyophilisate and instructions for use. A further embodiment of the present invention is method of stabilizing IL-6, an isoform or a fragment thereof, including the steps of mixing IL-6, an isoform or a fragment thereof, a compound of the formula C10-C18-alkyl trimethylammonium halogenide (I), wherein the compound is saturated or unsaturated and/or substituted or unsubstituted, or a salt thereof, wherein the concentration of the compound in the composition is about 0.15 to about 0.4%, and a serum.Type: GrantFiled: June 16, 2011Date of Patent: February 19, 2013Assignee: Roche Diagnostics Operations, Inc.Inventor: Christian Schneider
-
Publication number: 20130039972Abstract: The present invention concerns compositions comprising and methods of identification and use of targeting peptides for placenta or adipose tissue. In certain embodiments, the targeting peptides comprise part or all of SEQ ID NO:5-11, SEQ ID NO:13-22 or SEQ ID NO:144. The peptides may be attached to various therapeutic agents for targeted delivery. Adipose-targeting peptides may be used in methods for weight control, inducing weight loss and treating lipodystrophy syndrome. Adipose-targeting may also be accomplished using other binding moieties selectively targeted to adipose receptors, such as a prohibitin receptor protein complex. Placenta-targeting peptides may be used to interfere with pregnancy, induce labor and/or for targeted delivery of therapeutic agents to placenta and/or fetus. In other embodiments, receptors identified by binding to placenta-targeting peptides may be used to screen compounds for potential teratogenicity.Type: ApplicationFiled: July 26, 2012Publication date: February 14, 2013Inventors: Renata Pasqualini, Wadih Arap, Mikhail G. Kolonin
-
Publication number: 20130040884Abstract: Novel polypeptide derivatives having protracted profile of action.Type: ApplicationFiled: March 22, 2012Publication date: February 14, 2013Inventors: Jesper Lau, Thomas Kruse Hansen, Kjeld Madsen, Paw Bloch, Florencio Zaragoza Dorwald, Nils Langeland Johansen
-
Patent number: 8372388Abstract: A stable immunogenic product for the induction of antibodies against one or more antigenic proteins in a subject, characterized in that it comprises proteinaceous immunogenic heterocomplexes which are formed by associations between (i) antigenic protein molecules and (ii) proteinaceous carrier molecules and in that less than 40% of the antigenic proteins (i) are linked to the proteinaceous carrier molecules (ii) by a covalent bond.Type: GrantFiled: May 24, 2005Date of Patent: February 12, 2013Assignee: NeovacsInventors: Hélène Le Buanec, Daniel Zagury
-
Publication number: 20130034547Abstract: A chimeric therapeutic polypeptide of a pre-existing therapeutic polypeptide is disclosed, as are a method of enhancing folded stabilization and a pharmaceutical composition of the glycosylated chimer. The pre-existing and chimeric polypeptides have substantially the same length, substantially the same amino acid residue sequence, and exhibit at least one tight turn containing a sequence of four to about seven amino acid residues in which at least two amino acid side chains extend on the same side of the tight turn and are within less than about 7 ? of each other. The chimeric therapeutic polypeptide has the sequon Aro-(Xxx)n-(Zzz)p-Asn-Yyy-Thr/Ser (SEQ ID NO:001) within that tight turn sequence such that the side chains of the Aro, Asn and Thr/Ser amino acid residues project on the same side of the turn and are within less than about 7 ? of each other. That sequon is absent from the pre-existing therapeutic polypeptide.Type: ApplicationFiled: August 2, 2012Publication date: February 7, 2013Inventors: Jeffery W. Kelly, Joshua L. Price, Elizabeth K. Culyba, Evan T. Powers
-
Patent number: 8367054Abstract: Lyophilized and stabilized formulations of PEG-Interferon alpha conjugates and the process for their preparation that reduces lyophilization cycle time and are more cost competitive.Type: GrantFiled: November 16, 2007Date of Patent: February 5, 2013Assignee: Cadila Healthcare LimitedInventors: Sanjay Bandyopadhyay, Venkatesan Natarajan, Sanjeev Kumar Mendiratta, Pankaj Ramanbhai Patel
-
Publication number: 20130028930Abstract: The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.Type: ApplicationFiled: April 8, 2011Publication date: January 31, 2013Applicant: NOVOZYMES BIOPHARMA DK A/SInventors: Andrew Plumridge, Darrell Sleep, Inger Sandlie, Jan Terje Andersen, Jason Cameron, Leslie Evans, Steven Athwal, Elizabeth Allan, Esben Peter Friis
-
Publication number: 20130028867Abstract: The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious.Type: ApplicationFiled: April 4, 2011Publication date: January 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Jin Kim, Min Young Kim, Jin Sun Kim, Sung Hee Hong, Sung Youb Jung, Se Chang Kwon
-
Patent number: 8361966Abstract: The present invention demonstrates the myocardial protective effects of interleukin 11 in vivo, and provides preventive, therapeutic, or other types of drugs for heart disease using interleukin 11 as the active ingredient. The present invention, by utilizing the myocardial protective effects of interleukin 11, can suppress the progress of myocardial injury, prevent the onset of heart failure, or suppress the progress of heart failure.Type: GrantFiled: October 24, 2007Date of Patent: January 29, 2013Assignee: Osaka UniversityInventors: Junichi Azuma, Yasushi Fujio, Ryusuke Kimura, Makiko Maeda, Atsushi Arita, Masanori Obana, Takashi Ito, Tsuyoshi Fukuda
-
Patent number: 8361954Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.Type: GrantFiled: June 17, 2010Date of Patent: January 29, 2013Assignee: ZymoGenetics, Inc.Inventors: Sean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
-
Patent number: 8361470Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.Type: GrantFiled: May 17, 2012Date of Patent: January 29, 2013Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Mark W. Rixon, Stacey R. Dillon, Frederick J. Ramsdell, Cecile M. Krejsa, Eugene C. Yi
-
Patent number: 8362207Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: April 14, 2011Date of Patent: January 29, 2013Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Publication number: 20130022544Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: ApplicationFiled: July 16, 2012Publication date: January 24, 2013Applicant: NEW YORK UNIVERSITYInventors: Thomas M. Wisniewski, Fernando Goni
-
Patent number: 8357513Abstract: Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocyte progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.Type: GrantFiled: February 15, 1994Date of Patent: January 22, 2013Assignee: Genentech, Inc.Inventors: Dan L. Eaton, Frederic J. De Sauvage
-
Patent number: 8357515Abstract: The present provides a fusion protein comprising a latency associated peptide (LAP) and a pharmaceutically active agent in which the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising an aggrecanase proteolytic cleavage site.Type: GrantFiled: December 17, 2008Date of Patent: January 22, 2013Assignee: Queen Mary & Westfield CollegeInventors: Yuti Chernajovsky, Gillian Adams
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
-
Publication number: 20130011900Abstract: The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow conjugation. More specifically, the present invention relates to the aforementioned materials and methods wherein the water soluble polymer contains an active aminooxy group and wherein an oxime or hydrazone linkage is formed between the oxidized carbohydrate moiety and the active aminooxy group on the water soluble polymer, and wherein the conjugation is carried out in the presence of a nucleophilic catalyst.Type: ApplicationFiled: June 4, 2012Publication date: January 10, 2013Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Juergen Siekmann, Stefan Haider, Hanspeter Rottensteiner, Peter Turecek
-
Patent number: 8349311Abstract: The present invention relates to IL-2 mutants with increased affinity for the IL-2 alpha-receptor subunit (IL-2R?). The invention thus includes IL-2 mutants with improved biological potency. The invention also includes methods for directed evolution of IL-2? using yeast surface display to generate mutants with increased affinity for IL-2R?.Type: GrantFiled: April 15, 2011Date of Patent: January 8, 2013Assignee: Massachusetts Institute of TechnologyInventors: Karl Dane Wittrup, Balaji M. Rao, Douglas A. Lauffenburger
-
Publication number: 20130004415Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Inventors: Kamal Moudgil, Ying-hua Yang
-
Publication number: 20120329709Abstract: The present invention provides methods and materials by which glycosylation of glycoproteins can be regulated. Methods include the monitoring and regulation of parameters such that a glycoprotein having a desired product quality is obtained.Type: ApplicationFiled: May 25, 2010Publication date: December 27, 2012Inventors: Brian Edward Collins, Tiffany Guo, Lakshmanan Thiruneelakantapillai, Kevin Millea, Dorota A. Bulik
-
Publication number: 20120328558Abstract: Antibody-LIGHT fusion products or conjugates stimulate immunity against tumors and eradicate metastases. Tumor-specific antibodies coupled with LIGHT effectively target metastatic tumors and reduces cancer metastases.Type: ApplicationFiled: July 31, 2012Publication date: December 27, 2012Applicant: THE UNIVERSITY OF CHICAGOInventor: Yang-Xin Fu
-
Publication number: 20120328562Abstract: A method, and system, to induce remission in diseases characterized by excess production of sTNR and interleukin 2 has been developed. In the most preferred embodiment, the system consists of antibodies to sTNFR1, sTNFR2 and sIL2R immobilized in a column containing a material such as SEPHAROSE™. The patient is connected to a pheresis machine which separates the blood into the plasma and red cells, and the plasma is circulated through the column until the desired reduction in levels of sTNFR1, sTNFR2, and IL2 is achieved, preferably to less than normal levels. In the preferred method, patients are treated three times a week for four weeks. This process can be repeated after a period of time. Clinical studies showed reduction in tumor burden in patients having failed conventional chemotherapy and radiation treatments.Type: ApplicationFiled: May 22, 2012Publication date: December 27, 2012Inventor: M. Rigdon LENTZ
-
Publication number: 20120328519Abstract: The present invention relates to the novel compound classes of dendritic polyglycerol sulfates and sultanates as well as to their production and use for the treatment of diseases, particularly inflammatory diseases, and to their use as selectin inhibitors and selectin indicators. The dendritic polyglycerol sulfates and sulfonates are also suitable for imaging diagnostics, particularly with respect to inflammatory diseases.Type: ApplicationFiled: August 3, 2007Publication date: December 27, 2012Inventors: Rainer Haag, Jens Dernedde, Rudolf Tauber, Gesche Bernhard, Sven Enders, Heidemarie Weinhart, Arne Von Bonin, Ulrich Zügel, Holger Türk
-
Patent number: 8338575Abstract: The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7).Type: GrantFiled: May 18, 2011Date of Patent: December 25, 2012Assignee: Merck Patent GmbHInventors: Scott Lauder, Stephen D. Gillies
-
Patent number: 8338373Abstract: Methods and kits for preventing or reducing the likelihood of implantation failure or spontaneous abortion in a recipient of FET, ICSI, GIFT or ZIFT are provided. The methods include administering into a recipient of FET, ICSI, GIFT or ZIFT in need of such treatment an effective amount of granulocyte colony stimulating factor (G-CSF).Type: GrantFiled: October 27, 2009Date of Patent: December 25, 2012Assignee: Nora Therapeutics, Inc.Inventor: Darryl L. Carter
-
Patent number: 8338374Abstract: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).Type: GrantFiled: December 13, 2004Date of Patent: December 25, 2012Assignee: Pharmacia CorporationInventors: Manpreet S Wadhwa, Sandeep Nema, Advait Badkar
-
Patent number: 8338569Abstract: Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.Type: GrantFiled: August 4, 2009Date of Patent: December 25, 2012Assignee: Five Prime Therapeutics, Inc.Inventors: Shannon Marshall, Deborah H. Charych, Ali Sadra
-
Patent number: 8337826Abstract: The present invention relates to liquid formulations of human interferon-?. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-? in solution while retaining the molecular integrity.Type: GrantFiled: April 11, 2005Date of Patent: December 25, 2012Assignee: Rentschler Biotechnologie GmbHInventors: Michael Tschope, Thomas Siklosi, Peter Schroeder, Hans Hofer
-
Publication number: 20120321589Abstract: Disclosed herein are polypeptides which comprise all or part of an antibody linked to all or part of a cytokine. The cytokine sequences of the polypeptides have a modified heparin binding region which disrupts, inhibits, or reduces the ability of the cytokine to bind a heparin compound as compared to a corresponding cytokine having an unmodified heparin binding region. Also disclosed are methods of treating cancer, inducing cell proliferation, and reducing the non-specific binding and/or non-specific localization of the polypeptides.Type: ApplicationFiled: March 11, 2011Publication date: December 20, 2012Inventors: Manuel L. Penichet, Rosendo Luria-Perez, Gustavo Helguera
-
Patent number: 8333968Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: February 22, 2011Date of Patent: December 18, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8333958Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.Type: GrantFiled: January 11, 2011Date of Patent: December 18, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
-
Publication number: 20120316322Abstract: This invention provides a crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structure model of said interferon useful for drug screening and/or drug design and the mimetic of said interferon. The invention further provides methods of designing and using new recombinant interferons with altered spatial configuration and three-dimensional structure.Type: ApplicationFiled: June 7, 2012Publication date: December 13, 2012Inventor: Guangwen WEI
-
Publication number: 20120315245Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: ApplicationFiled: November 26, 2010Publication date: December 13, 2012Applicant: CENTRO DE INMUNOLOGIA MOLECULAR (CIM)Inventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Agustin Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
-
Patent number: 8329869Abstract: Modified interferon beta polypeptides and uses thereof are provided.Type: GrantFiled: January 6, 2012Date of Patent: December 11, 2012Assignee: Ambrx, Inc.Inventors: Vadim Kraynov, Nick Knudsen, Anna-Maria A. Hays Putnam, Denise Krawitz, Jason Pinkstaff, Heather Myler
-
Patent number: 8329431Abstract: The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.Type: GrantFiled: August 26, 2011Date of Patent: December 11, 2012Assignee: UCB Pharma S.A.Inventors: Ralph Adams, Andrew George Popplewell, Stephen Edward Rapecki, Simon Peter Tickle
-
Patent number: 8329160Abstract: The present invention relates to a method of treating cancers, especially those showing resistance to classical anti-pro liferative chemotherapy drugs. Further, the invention provides a specific interferon alpha sequential regimen for treating cancers, especially those showing resistance to classical anti-proliferative chemotherapy drugs such as stem cell driven cancers. More specifically, the invention relates to a use of IFN alpha for the preparation of a pharmaceutical formulation for the treatment of cancers wherein the pharmaceutical formulation is to be administered following a sequential administration pattern i.e. an induction period wherein a therapeutically effective amount of IFN alpha is administered, a period during which no IFN alpha is administrated and a chemotherapy period wherein a therapeutically effective amount of a chemotherapeutic agent is administered.Type: GrantFiled: June 13, 2008Date of Patent: December 11, 2012Assignee: HI-StemInventors: Andreas Trumpp, Marieke Essers
-
Patent number: 8329657Abstract: Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.Type: GrantFiled: August 11, 2011Date of Patent: December 11, 2012Assignee: The Trustees of the University of PennsylvaniaInventors: Mark L. Tykocinski, Marjaneh Razmara
-
Publication number: 20120308482Abstract: Cytokine IFN? nucleic acids from the Cynomolgus monkey are useful for expression of IFN? proteins that are functional homologs of human IFN?. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of IFN?, the generation and testing of IFN? modulators and related activities.Type: ApplicationFiled: February 16, 2011Publication date: December 6, 2012Inventors: Chichi Huang, Jarrat Jordan, Jessica Schreiter
-
Publication number: 20120308520Abstract: This invention provides crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Applicant: SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.Inventors: Guangwen Wei, Dacheng Wang
-
Publication number: 20120309936Abstract: Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces the ability of a junctional epitope to bind to MHC Class II, thereby reducing its interaction with a T-cell receptor. Methods of the invention involve analyzing, changing, or modifying one or more amino acids in the junction region of a fusion protein in order to identify a T-cell epitope and reduce its ability to interact with a T cell receptor. Compositions and methods of the invention are useful in therapy.Type: ApplicationFiled: May 26, 2011Publication date: December 6, 2012Applicant: Merck Patent GmbHInventors: Stephen D. Gillies, Jeffrey Way, Anita A. Hamilton
-
Patent number: 8323636Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: GrantFiled: July 28, 2011Date of Patent: December 4, 2012Assignee: Prolor Biotech Ltd.Inventors: Fuad Fares, Udi Eyal Fima
-
Patent number: 8323634Abstract: Described herein are compositions and methods for treating, preventing and ameliorating diseases and conditions characterized by a lower than normal white blood cell count, such as leukopenia and neutropenia. The compositions and methods include recombinant human albumin-human granulocyte colony stimulating factor. Pharmaceutical formulations including the recombinant fusion protein, and methods of making such formulations are also described.Type: GrantFiled: January 15, 2010Date of Patent: December 4, 2012Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Jason Benjamin Bock, Xia Luo
-
Publication number: 20120302733Abstract: Methods to derive novel hybrid type 1 interferons that are broadly active against highly pathogenic viruses of biodefense significance are described. Libraries of hybrid interferon genes were produced using gene shuffling, the proteins were expressed, and screened for activity against viruses of interest. Sequences of several broadly active hybrid interferons are described.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Inventors: Hal S. Padgett, Fakhrieh S. Vojdani, Andrew A. Vaewhongs
-
Publication number: 20120301393Abstract: The present invention refers to novel recombinant proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B). Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component.Type: ApplicationFiled: December 14, 2010Publication date: November 29, 2012Inventors: Arnd Steuernagel, Erik Fiedler, Markus Fiedler, Anja Kunert, Joerg Nerkamp, Thomas Goettler, Manja Gloser, Ilka Haenssgen
-
Patent number: 8318491Abstract: The present invention relates to an agent for differentiating hematopoietic stem cells into natural killer cells and a method for the differentiation, more precisely an agent for differentiating hematopoietic stem cells into natural killer cells comprising YC-I [3-(5?-hydroxymethyl-2?-furyl)-1-benzylindazole] or IL-21 (Interleukin-21) as an active ingredient and a method for differentiating hematopoietic stem cells into natural killer cells using the same. The YC-I and IL-21 regulate the differentiation of hematopoietic stem cells into natural killer cells and increase the killing activity of NK cells. Therefore, the agent for NK cell differentiation of the present invention can be effectively used for cell therapy for the treatment of cancer by regulating the differentiation of hematopoietic stem cells into natural killer cells having tumor cell killing activity.Type: GrantFiled: October 2, 2007Date of Patent: November 27, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Inpyo Choi, SukRan Yoon, Sohyun Yun, Jin Woong Chung
-
Patent number: 8318197Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: January 17, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
-
Patent number: 8313739Abstract: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.Type: GrantFiled: March 7, 2011Date of Patent: November 20, 2012Assignee: ZymoGenetics, Inc.Inventor: Paul O. Sheppard